Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Additional Phase 2 Study of CK-2127107 in Patients with COPD Set to Initiate 1H of 2016

Source Link:: http://services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRndhUzUwWlc1cmQybDZZWEprTG1OdmJTOWtiM2R1Ykc5aFpDNXdhSEEvWVdOMGFXOXVQVkJFUmlacGNHRm5aVDB4TURjNU5EQTBNaVp6ZFdKemFXUTlOVGM9JnR5cGU9MiZmbj1DeXRva2luZXRpY3NJbmMucGRm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

TSE:4503

100%

CYTK

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "An additional Phase 2 clinical trial to be conducted by Astellas in collaboration with Cytokinetics, will study CK-2127107 in patients with chronic obstructive pulmonary disorder (“COPD”) and is expected to be initiated in the first half of 2016."

http://services.corp...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 30, 2016

Occurred Source:

http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-newsArticle&ID=2181125

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Ck-2127107, Copd, Chronic Obstructive Pulmonary Disease, Phase 2 Study